Lupus and Epstein-Barr

Current Opinion in Rheumatology

Volumn 24, Issue 4, 2012, Pages 383-388

  James, Judith A ^a,b   Robertson, Julie M ^a  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

environmental factors; Epstein Barr virus; etiology; systemic lupus erythematosus

Indexed keywords

CD69 ANTIGEN; DOUBLE STRANDED DNA; EPSTEIN BARR VIRUS ANTIGEN; INTERFERON; VIRUS CAPSID ANTIGEN;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL STIMULATION; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; CYTOTOXICITY; DNA VIRUS; EPIGENETICS; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; GENE EXPRESSION; GEOGRAPHY; HUMAN; HUMORAL IMMUNITY; IMMUNOREGULATION; MOLECULAR MIMICRY; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SEROCONVERSION; SEROLOGY; SEROPREVALENCE; SYSTEMIC LUPUS ERYTHEMATOSUS; VIRUS GENE; VIRUS LOAD; VIRUS PATHOGENESIS; VIRUS REACTIVATION;

DENDRITIC CELLS; EPIGENESIS, GENETIC; EPSTEIN-BARR VIRUS INFECTIONS; GENE EXPRESSION PROFILING; HERPESVIRUS 4, HUMAN; HUMANS; INTERFERONS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MOLECULAR MIMICRY; T-LYMPHOCYTE SUBSETS; VIRAL LOAD;

EID: 84862149030     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3283535801     Document Type: Review

References (43)

1. Sestak AL, Fü rnrohr BG, Harley JB, Merrill JT, et al. The genetics of systemic lupus erythematosus and implications for targeted therapy. Ann Rheum Dis 2011; 70:i37-i43.
2. Deng Y, Tsao BP. Genetic susceptibility to systemic lupus erythematosus in the genomic era. Nat Rev Rheumatol 2010; 6:683-692.
3. Lockshin MD. Sex differences in autoimmune disease. Lupus 2006; 15:753-756.
4. Sarzi-Puttini P, Atzeni F, Iaccarino L, Doria A. Environment and systemic lupus erythematosus: an overview. Autoimmunity 2005; 38:465-472. (Pubitemid 43101780)
5. Esen BA, Yilmaz G, Uzun S, Ozdamar M, et al. Serologic response to Epstein-Barr virus antigens in patients with systemic lupus erythematosus: a controlled study. Rheumatol Int 2012; 32:79-83.
6. Berner BR, Tary-Lehmann M, Yonkers NL, Askari AD, et al. Phenotypic and functional analysis of EBV-specific memory CD8 cells in SLE. Cell Immunol 2005; 235:29-38. (Pubitemid 41483031)
7. Berkun Y, Zandman-Goddard G, Barzilai O, Boaz M, et al. Infectious antibodies in systemic lupus erythematosus patients. Lupus 2009; 18:1129-1135.
8. Fattal I, Shental N, Mevorach D, Anaya JM, et al. An antibody profile of systemic lupus erythematosus detected by antigen microarray. Immunology 2010; 130:337-343.
9. Chen DY, Chen YM, Lan JL, Chen HH, et al. Polymyositis/dermatomyositis and nasopharyngeal carcinoma: the Epstein-Barr virus connection? J Clin Virol 2010; 49:290-295.
10. Yadav P, Tran H, Ebegbe R, Gottlieb P, et al. Antibodies elicited in response to EBNA-1 may cross-react with dsDNA. PLoS One 2011; 6:e14488.
11. Sundar K, Jacques S, Gottlieb P, Villars R, et al. Expression of the Epstein-Barr virus nuclear antigen-1 (EBNA-1) in the mouse can elicit the production of antidsDNA and anti-Sm antibodies. J Autoimmun 2004; 23:127-140. (Pubitemid 39485794)
12. Sawalha AH. Epigenetics and T-cell immunity. Autoimmunity 2008; 41: 245-252. (Pubitemid 351593855)
13. Francis L, Perl A. Infection in systemic lupus erythematosus: friend or foe? Int J Clin Rheumtol 2010; 5:59-74.
14. Blank M, Shoenfeld Y, Perl A. Cross-talk of the environment with the host genome and the immune system through endogenous retroviruses in systemic lupus erythematosus. Lupus 2009; 18:1136-1143.
15. Niller HH, Wolf H, Ay E, Minarovits J. Epigenetic dysregulation of Epstein-Barr virus latency and development of autoimmune disease. In: Ballestar E, editor. Advances in experimental medicine and biology: epigenetic contributions in autoimmune disease. New York, NY: Springer US; 2011. pp. 82-102.
16. Poole BD, Templeton AK, Guthridge JM, Brown EJ, et al. Aberrant Epstein-Barr viral infection in systemic lupus erythematosus. Autoimmun Rev 2009; 8:337-342.
17. Tsokos GC, Magrath IT, Balow JE. Epstein-Barr virus induces normal B cell responses but defective suppressor T cell responses in patients with systemic lupus erythematosus. J Immunol 1983; 131:1797-1801. (Pubitemid 13006895)
18. Kang I, Quan T, Nolasco H, Park SH, et al. Defective control of latent Epstein-Barr virus infection in systemic lupus erythematosus. J Immunol 2004; 172:1287-1294. (Pubitemid 38113792)
19. Larsen M, Sauce D, Deback C, Arnaud L, et al. Exhausted cytotoxic control of Epstein-Barr virus in human lupus. PLoS Pathog 2011; 7:e1002328.
20. Quan TE, Roman RM, Rudenga BJ, Holers VM, et al. Epstein-Barr virus promotes interferon-alpha production by plasmacytoid dendritic cells. Arthritis Rheum 2010; 62:1693-1701.
21. Harley JB, James JA. Everyone comes from somewhere: systemic lupus erythematosus and Epstein-Barr virus induction of host interferon and humoral anti-Epstein-Barr nuclear antigen 1 immunity. Arthritis Rheum 2010; 62: 1571-1575.
22. Vinuesa CG, Rigby RJ, Yu D. Logic and extent of miRNA-mediated control of autoimmune gene expression. Int Rev Immunol 2009; 28:112-138.
23. Te JL, Dozmorov IM, Guthridge JM, Nguyen KL, et al. Identification of unique microRNA signature associated with lupus nephritis. PLoS One 2010; 5:e10344.
24. Stagakis E, Bertsias G, Verginis P, Nakou M, et al. Identification of novel microRNA signatures linked to human lupus disease activity and pathogenesis: miR-21 regulates aberrant T cell responses through regulation of PDCD4 expression. Ann Rheum Dis 2011; 70:1496-1506.
25. Agmon-Levin N, Blank M, Paz Z, Shoenfeld Y. Molecular mimicry in systemic lupus erythematosus. Lupus 2009; 18:1181-1185.
26. Niller HH, Wolf H, Minarovits J. Regulation and dysregulation of Epstein-Barr virus latency: Implications for the development of autoimmune diseases. Autoimmunity 2008; 41:298-328. (Pubitemid 351593860)
27. Poole BD, Scofield RH, Harley JB, James JA. Epstein-Barr virus and molecular mimicry in systemic lupus erythematosus. Autoimmunity 2006; 39:63-70. (Pubitemid 43878521)
28. James JA, Harley JB, Scofield RH. Epstein-Barr virus and systemic lupus erythematosus. Curr Opin Rheumatol 2006; 18:462-467. (Pubitemid 44200328)
29. Via CS. Implications of the parent-into-F1 model for human lupus pathogenesis: roles for cytotoxic T lymphocytes and viral pathogens. Curr Opin Rheumatol 2010; 22:493-498; doi: 10.1097/BOR.0b013e32833b0174.
30. Ulff-Moller CJ, Nielsen NM, Rostgaard K, Hjalgrim H, et al. Epstein-Barr virusassociated infectious mononucleosis and risk of systemic lupus erythematosus. Rheumatology (Oxford) 2010; 49:1706-1712.
31. Zandman-Goddard G, Berkun Y, Barzilai O, Boaz M, et al. Exposure to Epstein-Barr virus infection is associated with mild systemic lupus erythematosus disease. Ann N Y Acad Sci 2009; 1173:658-663.
32. Ramos-Casals M, Cuadrado MJ, Alba P, Sanna G, et al. Clinical guidelines for the management of acute viral infections in patients with systemic lupus erythematosus. Minerva Med 2009; 100:437-446.
33. Hongbo C, Hongzhen M, Lingzhi H, Maosheng X, et al. Secondary neuropsychiatric manifestations caused by Epstein-Barr virus encephalitis in a new onset systemic lupus erythematosus patient. Rheumatol Int 2011.
34. Tsukamoto N, Handa H, Yokohama A, Mitsui T, et al. Long-term follow-up of EBV-positive lymphoproliferative disorders in a patient with systemic lupus erythematosus. Med Mol Morphol 2011; 44:237-241.
35. Tsang HH, Trendell-Smith NJ, Wu AK, Mok MY. Diffuse large B-cell lymphoma of the central nervous system in mycophenolate mofetil-treated patients with systemic lupus erythematosus. Lupus 2010; 19:330-333.
36. Moon SJ, Kwok SK, Park KS, Kim WU, et al. Simultaneous presentation of hemophagocytic syndrome and mesenteric vasculitis in a patient with systemic lupus erythematosus. Mod Rheumatol 2011; 21:330-333.
37. Gionanlis L, Katsounaros M, Bamihas G, Fragidis S, et al. Kikuchi-Fujimoto disease and systemic lupus erythematosus: the EBV connection? Ren Fail 2009; 31:144-148.
38. Harley JB, Harley ITW, Guthridge JM, James JA. The curiously suspicious: a role for Epstein-Barr virus in lupus. Lupus 2006; 15:768-777.
39. Peters AL, Stunz LL, Meyerholz DK, Mohan C, et al. Latent membrane protein 1, the EBV-encoded oncogenic mimic of CD40, accelerates autoimmunity in B6.Sle1 mice. J Immunol 2010; 185:4053-4062.
40. Arcipowski KM, Stunz LL, Graham JP, Kraus ZJ, et al. Molecular mechanisms of TNFR-associated factor 6 (TRAF6) utilization by the oncogenic viral mimic of CD40, latent membrane protein 1 (LMP-1). J Biol Chem 2011; 286:9948-9955.
41. Igawa T, Nakashima H, Sadanaga A, Masutani K, et al. Deficiency in EBVinduced gene 3 (EBI3) in MRL/lpr mice results in pathological alteration of autoimmune glomerulonephritis and sialadenitis. Mod Rheumatol 2009; 19:33-41.
42. Gross AJ, Hochberg D, Rand WM, Thorley-Lawson DA. EBV and systemic lupus erythematosus: a new perspective. J Immunol 2005; 174:6599-6607. (Pubitemid 40705620)
43. Stunz LL, Busch LK, Munroe ME, Sigmund CD, et al. Expression of the cytoplasmic tail of LMP1 in mice induces hyperactivation of B lymphocytes and disordered lymphoid architecture. Immunity 2004; 21:255-266. (Pubitemid 39094054)